LOC
CARsgen and Galapagos Resume CAR-T Trials Without Restrictions
CAR-T trials, CARsgen, Galapagos, cancer treatment, clinical trials
Siemens Healthineers Expands into Europe with Acquisition of Novartis’ Radiodiagnostic Manufacturing Network
Siemens Healthineers, Novartis, Acquisition, Radiodiagnostic Manufacturing Network, Europe, PET Radiopharmaceuticals
Galapagos Investor Seeks to Influence Company Control, Citing Undervaluation
Galapagos, investor influence, undervaluation, biotech, corporate control
Kyowa Kirin Divests China Unit and Reduces Small-Molecule Discovery Efforts
Kyowa Kirin, China business, small-molecule discovery, restructuring, Asia Pacific, pharmaceuticals
Galapagos Halts BCMA CAR-T Study Due to Parkinsonism Case
Galapagos, BCMA CAR-T, Parkinsonism, multiple myeloma, CAR-T therapy, clinical trial, PAPILIO-1 study, GLPG5301
Galapagos Halts CAR-T Cell Therapy Trial Due to Parkinsonism Case
Galapagos, CAR-T cell therapy, Parkinsonism, clinical trial, patient enrollment, BCMA-directed therapy, multiple myeloma
Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration
Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy
BioNTech Secures $145M from CEPI to Expand mRNA Vaccine Production in Africa
BioNTech, CEPI, mRNA vaccine production, Africa, vaccine equity, public health security
Galapagos Expands Decentralized CAR-T Manufacturing Across the Nation with Strategic Partnership
Galapagos, decentralized CAR-T manufacturing, partnership, nationwide expansion, cancer treatment, immunotherapy, biotechnology, healthcare innovation.
Vertex’s Acquisition of Alpine Immune Sciences for Povetacicept: Humira-like Potential in IgAN, but Indication Variations Matter
Vertex, Alpine Immune Sciences, Povetacicept (ALPN-303), IgA nephropathy (IgAN), Humira-like potential, Multiple autoimmune diseases